Next Article in Journal
Royal Jelly and Its Components Promote Healthy Aging and Longevity: From Animal Models to Humans
Next Article in Special Issue
Age-Induced Differential Changes in the Central and Colonic Human Circadian Oscillators
Previous Article in Journal
The Roles of Sex Hormones in the Course of Atopic Dermatitis
Review

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)

1
Department of Neurodegeneration Diagnostics, Medical University of Białystok, 15-269 Białystok, Poland
2
Department of Biochemical Diagnostics, University Hospital of Białystok, 15-269 Białystok, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(19), 4661; https://doi.org/10.3390/ijms20194661
Received: 30 August 2019 / Revised: 13 September 2019 / Accepted: 16 September 2019 / Published: 20 September 2019
Although the causative role of the accumulation of amyloid β 1–42 (Aβ42) deposits in the pathogenesis of Alzheimer′s disease (AD) has been under debate for many years, it is supposed that the toxicity soluble oligomers of Tau protein (TauOs) might be also the pathogenic factor acting on the initial stages of this disease. Therefore, we performed a thorough search for literature pertaining to our investigation via the MEDLINE/PubMed database. It was shown that soluble TauOs, especially granular forms, may be the most toxic form of this protein. Hyperphosphorylated TauOs can reduce the number of synapses by missorting into axonal compartments of neurons other than axon. Furthermore, soluble TauOs may be also responsible for seeding Tau pathology within AD brains, with probable link to AβOs toxicity. Additionally, the concentrations of TauOs in the cerebrospinal fluid (CSF) and plasma of AD patients were higher than in non-demented controls, and revealed a negative correlation with mini-mental state examination (MMSE) scores. It was postulated that adding the measurements of TauOs to the panel of CSF biomarkers could improve the diagnosis of AD. View Full-Text
Keywords: Alzheimer′s disease; tau oligomers; neurodegeneration; protein misfolding; tauopathy; CSF; plasma; serum Alzheimer′s disease; tau oligomers; neurodegeneration; protein misfolding; tauopathy; CSF; plasma; serum
Show Figures

Graphical abstract

MDPI and ACS Style

Mroczko, B.; Groblewska, M.; Litman-Zawadzka, A. The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD). Int. J. Mol. Sci. 2019, 20, 4661. https://doi.org/10.3390/ijms20194661

AMA Style

Mroczko B, Groblewska M, Litman-Zawadzka A. The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD). International Journal of Molecular Sciences. 2019; 20(19):4661. https://doi.org/10.3390/ijms20194661

Chicago/Turabian Style

Mroczko, Barbara, Magdalena Groblewska, and Ala Litman-Zawadzka. 2019. "The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)" International Journal of Molecular Sciences 20, no. 19: 4661. https://doi.org/10.3390/ijms20194661

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop